Skip to main content
    R

    RenovoRx Inc (RNXT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.95
    -0.09 (-8.18%)

    Market Cap: $50.18M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    RenovoRx Inc (RNXT) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect RenovoRx (RNXT) to earn -$0.27 per share in the fiscal year ending Dec 31, 2026, on revenue of $3.86M. Of 4 analysts, 4 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 4 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy00.0%
    Buy4100.0%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    4

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 196.1%.

    Fiscal year ending Dec 31, 2026
    -$0.27
    EPS consensus, revenue $3.86M
    Fiscal year ending Dec 31, 2027
    -$0.12
    EPS consensus, revenue $11.43M
    Next report
    Mar 29, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.27-$0.27 to -$0.271$3.86M$3.70M to $4.04M4
    Dec 31, 2027-$0.12-$0.20 to -$0.042$11.43M$10.00M to $14.01M4

    Quarterly Estimates

    The EPS consensus rises from -$0.06 for the quarter ending Dec 31, 2026 to -$0.05 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.06-$0.07 to -$0.036$1.37M$1.14M to $1.58M6
    Mar 31, 2027-$0.05-$0.06 to -$0.032$1.54M$1.40M to $1.71M3

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 1 upward and 1 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202610
    Fiscal year ending Dec 31, 202700
    Quarter ending Mar 31, 202701

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.31.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$0.27-$0.27-$0.27-$0.27-$0.31N/A
    Fiscal year ending Dec 31, 2027-$0.12-$0.12-$0.12-$0.12-$0.15N/A
    Quarter ending Mar 31, 2027-$0.05-$0.05-$0.05-$0.05-$0.07N/A

    Frequently Asked Questions About RNXT

    What is the RNXT stock forecast?

    Consensus analyst estimates put RenovoRx's EPS at -$0.27 for the fiscal year ending Dec 31, 2026, on revenue of $3.86M. The consensus rating from 4 analysts is Buy.

    How do analysts rate RNXT stock?

    Of 4 analysts covering RenovoRx, 0 rate it Strong Buy, 4 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from RNXT next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.27, with estimates from -$0.27 to -$0.27 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.12, with estimates from -$0.20 to -$0.04 from 2 analysts.

    What revenue do analysts expect from RenovoRx next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $3.86M, with estimates from $3.70M to $4.04M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $11.43M, with estimates from $10.00M to $14.01M.

    How many analysts cover RNXT?

    4 analysts rate RenovoRx stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.